For example, Bevacizumab (Avastin), an antibody that targets VEGF, was the first anti-angiogenic drug approved by FDA in combination with chemotherapy to treat several types of cancers including metastatic colorectal cancer, NSCLC, Glioblastoma, mRCC, and cervical cancer. This evidence concerns the gene VEGFA and cancer.